<i>CCNE1</i> Is a Putative Therapeutic Target for <i>ARID1A</i>-Mutated Ovarian Clear Cell Carcinoma.

Int J Mol Sci · 2021 · PMC8198755 · PMID 34070839

Europe PMC DOI

hedged sentences

0.1910

closest p · 3.8× alpha

0.8190

boldest claim

The sentences

showed a trendp = 0.191not close (p > 0.1)

The si-CCNE1 and cisplatin (60 μg/kg) with an atelocollagen group showed a trend of decreasing tumor weight compared with the si-control and cisplatin (60 μg/kg) group (274.3 ± 136.4 vs. 420.6 ± 216.4, p = 0.191) ( Figure 7 B). 3.

also in 53,322 other papers

an increasing trendp = 0.819not close (p > 0.1)

Knockdown of CCNE1 showed an increasing trend in the proportion of the sub-G1 phase compared with that in the control group at 48 h and 72 h (9.5 ± 4.6 vs. 8.5 ± 5.4, p = 0.819; 19.2 ± 11.5 vs. 8.4 ± 2.5, p = 0.186, respectively), and a decrease in the S phase (22.1 ± 2.6 vs. 25.8 ± 4.4, p = 0.283; 18.8 ± 3.3 vs. 24.0 ± 1.4, p = 0.066, respectively) ( Figure 4 ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.